Cortagen — Khavinson bioregulator — heart / cardiac
Cortagen targets cardiac tissue. Proposed to activate cardiomyocyte-specific gene expression programs that decline with aging. Animal studies show improved myocardial recovery after ischemia, enhanced mitochondrial respiration, ATP synthesis improvement, and reduced oxidative stress. Limited clinical data.
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Khavinson bioregulator — heart / cardiac
Mechanism of Action
Cortagen targets cardiac tissue. Proposed to activate cardiomyocyte-specific gene expression programs that decline with aging. Animal studies show improved myocardial recovery after ischemia, enhanced mitochondrial respiration, ATP synthesis improvement, and reduced oxidative stress. Limited clinical data.
Regulatory Status
Not FDA approved. Research peptide. Not approved as pharmaceutical drug in Russia.
Evidence Level
Very Low — animal studies (Korkushko et al.) and limited small clinical observations only. No published RCTs in humans.